Laidlaw Downgrades Intercept Pharmaceuticals (ICPT) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Intercept (ICPT) OCA Off to Gradual Start in PBC, BMO Capital Notes; PT to $218
August 4, 2016 1:55 PM EDTBMO Capital analyst M. Ian Somaiya trimmed his price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $218.00 (from $219.00) but maintained an Outperform rating following the sell-off following 2Q16 results is primarily driven by a lack of visibility into the timing of meaningful sales for recently... More
Intercept Pharma (ICPT) Posts Mixed Q2 Results: Updates on Ocaliva
August 4, 2016 7:06 AM EDTIntercept Pharma (NASDAQ: ICPT) reported Q2 EPS of ($3.14), $0.55 better than the analyst estimate of ($3.69). Revenue for the quarter came in at $5.52 million versus the consensus estimate of $1.72 million.
Ocaliva Commercial Update
Following a 17 to 0 FDA Advisory Committee vote in favor of... More
